Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
作者： Hilary Hewes , Judith A. Smith , Claire Verschraegen
DOI: 10.1385/1-59259-866-8:207
关键词:
摘要: Camptothecin (CPT) compounds are one of the newer classes anticancer agents introduced over past decade. Early investigational trials with parent compound, CPT, derived from bark Camptotheca accuminata tree, was into clinical in late 1970s. Because its poor water solubility, CPT formulated sodium bicarbonate, which opened 20(S) lactone ring and caused significant toxicity inconsistent activity. Hence, development camptothecin as an agent halted (1).
springer.com
springerlink.com参考文章(39)
O S Selawry, F M Muggia, M H Cohen, P J Creaven, H H Hansen, Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer chemotherapy reports. ,vol. 56, pp. 515- 521 ,(1972)
Beppino C. Giovanella, Ethan A. Natelson, Hellmuth R. Hinz, Nicholas J. Harris, Pharmacokinetics of the in Vivo and in Vitro Conversion of 9-Nitro-20(S)-camptothecin to 9-Amino-20(S)-camptothecin in Humans, Dogs, and Mice Cancer Research. ,vol. 54, pp. 3096- 3100 ,(1994)
Beppino C. Giovanella, Milan Potmesil, Hellmuth R. Hinz, Anthony J. Kozielski, John S. Stehlin, Robert Silber, Complete Growth Inhibition of Human Cancer Xenografts in Nude Mice by Treatment with 20-(S)-Camptothecin Cancer Research. ,vol. 51, pp. 3052- 3055 ,(1991)
Jeffrey G Supko, Rocio Garcia-Carbonero, Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clinical Cancer Research. ,vol. 8, pp. 641- 661 ,(2002)
A P Kudelka, D Tresukosol, C L Edwards, R S Freedman, C Levenback, P Chantarawiroj, C Gonzalez de Leon, E E Kim, T Madden, B Wallin, M Hord, C Verschraegen, M Raber, J J Kavanagh, Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Journal of Clinical Oncology. ,vol. 14, pp. 1552- 1557 ,(1996) , 10.1200/JCO.1996.14.5.1552
A Ardizzoni, H Hansen, P Dombernowsky, T Gamucci, S Kaplan, P Postmus, G Giaccone, B Schaefer, J Wanders, J Verweij, Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Journal of Clinical Oncology. ,vol. 15, pp. 2090- 2096 ,(1997) , 10.1200/JCO.1997.15.5.2090
Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd, Scott Z. Fields, J.P. Kleisbauer, Nick G. Chrysson, David J. Stewart, Peter I. Clark, Martin C. Palmer, Alain Depierre, James Carmichael, Jacqueline B. Krebs, Graham Ross, Stephen R. Lane, Richard Gralla, Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 17, pp. 658- 667 ,(1999) , 10.1200/JCO.1999.17.2.658
E K Rowinsky, L B Grochow, C B Hendricks, D S Ettinger, A A Forastiere, L A Hurowitz, W P McGuire, S E Sartorius, B G Lubejko, S H Kaufmann, Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology. ,vol. 10, pp. 647- 656 ,(1992) , 10.1200/JCO.1992.10.4.647
Claire F Verschraegen, Elora Gupta, Evelyne Loyer, John J Kavanagh, Andrzej P Kudelka, Ralph S Freedman, Creighton L Edwards, Nick Harris, Melissa Steger, Veronica Steltz, Beppino C Giovanella, John S Stehlin, A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anti-Cancer Drugs. ,vol. 10, pp. 375- 383 ,(1999) , 10.1097/00001813-199904000-00005
Beppino Giovanella, John Stehlin, Hellmuth Hinz, Anthony Kozielski, Nicholas Harris, Dana Vardeman, Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). International Journal of Oncology. ,vol. 20, pp. 81- 88 ,(2002) , 10.3892/IJO.20.1.81